Paracetamol Discontinuation in the Elderly After Long-term Consumption
Unknown statusNot applicableNCT04523740
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
To investigate if long-term treatment of paracetamol can be discontinued without no worsening on pain, health-related quality-of-life and level of function compared to continuing paracetamol treatment in patients aged 65 years or more.
Study details
- Official title
- Paracetamol Discontinuation in the Elderly After Long-term Consumption
- Conditions
- Pain, Chronic
- Pain, Medication
- Pain, Discontinuation
- Interventions
- Sponsor
- University Hospital Bispebjerg and Frederiksberg
- Start date
- 2020-08
- Primary completion
- 2021-12
- Sex
- All
- Age range
- from 65 Years
- Results posted
- No results posted in this snapshot
- Countries
- Denmark
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * 65 years or more * Regular daily users of 3 to 4 grams of paracetamol for at least 6 months prior to enrollment Exclusion Criteria: * Malignant pain cf. their medical records * Patients using other regular analgesics cf. indication on prescription * Patients receiving paracetamol tablets with modified release or sustained release * Patients in warfarin treatment * Patients with terminal illnesses, cf. their medical records. * Patients receiving dosages dispensed by their pharmacy * Mini-Mental State Examination (MMSE) score less than 25 * Patients with or suspected to have COVID-19.
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT04523740